PBYI vs SLN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
PBYI presents a stable Piotroski F-Score of 4/9, but the stock is currently trading at a significant premium to its Graham Number ($5.96) and Intrinsic Value ($4.27). While the company maintains impressive gross margins (74.53%) and a strong ROE (27.97%), these are offset by a concerning -34.4% YoY earnings growth. With a technical trend score of 10/100 and an analyst target price of $5.00, the current price of $7.24 appears fundamentally overextended. Bearish insider activity from the CEO and CFO further suggests a lack of confidence in near-term upside.
SLN exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical financial weakness. The company has experienced a catastrophic revenue collapse of -99.90% YoY, rendering traditional valuation metrics like the P/S ratio (636.26) meaningless. While the current ratio of 8.72 suggests a temporary liquidity cushion, the operating margin of -37,150% and negative ROE of -90.27% signal an unsustainable burn rate. The recent price surge is entirely decoupled from financial performance and appears purely speculative.
Compare Another Pair
Related Comparisons
PBYI vs SLN: Head-to-Head Comparison
This page compares Puma Biotechnology, Inc. (PBYI) and Silence Therapeutics plc (SLN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.